DDInter714 DDInter782
Fedratinib, also known as SAR302503 and TG101348, is a tyrosine kinase inhibitor used to treat intermediate-2 and high risk primary and secondary myelofibrosis.[A183176,L8090] It is an anilinopyrimidine derivative. Fedratinib was granted FDA approval on August 16, 2019.
In April 2018, the U.S. Food and Drug Administration (FDA) and the Swiss company Helsinn approved the intravenous formulation of AKYNZEO® (NEPA, a fixed antiemetic combination of fosnetupitant, 235mg, and palonosetron, 0.25mg) as an alternative treatment option for patients experiencing chemotherapy-induced nausea and vomiting . Fosnetupitant is the pro-drug form of netupitant [FDA label]. Generally, 25% to 30% of patients with a diagnosis of cancer receive chemotherapy as a treatment modality and 70% to 80% of these patients undergoing chemotherapy treatment may experience nausea and vomiting as major side effects. Considered one of the most distressing side effects of chemotherapy, nausea and vomiting has an immense impact on the quality of life of patients receiving certain antineoplastic therapies .
Fedratinib {u} may cause a minor interaction that can limit clinical effects when taken with {v} Mirabegron
Fedratinib {u} may cause a minor interaction that can limit clinical effects when taken with {v} Darolutamide
Fedratinib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Pralsetinib
Fedratinib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Abametapir
Fedratinib {u} may lead to a major life threatening interaction when taken with {v} Tamoxifen
Fedratinib {u} may lead to a major life threatening interaction when taken with {v} Lurbinectedin
Fedratinib may cause a minor interaction that can limit clinical effects when taken with Mirabegron
Fedratinib may cause a minor interaction that can limit clinical effects when taken with Darolutamide
Fedratinib may cause a moderate interaction that could exacerbate diseases when taken with Pralsetinib
Fedratinib may cause a moderate interaction that could exacerbate diseases when taken with Abametapir
Fedratinib may lead to a major life threatening interaction when taken with Tamoxifen
Fedratinib may lead to a major life threatening interaction when taken with Lurbinectedin